Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

Registry ID

EUCTR2010-021003-24

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Amgen Inc

Start date

2011-10-10

Last update

2026-08-16

Conditions

• Acute heart failure

Summary

The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure (AHF).

Locations

• , , UK
• , , Greece
• , , Slovakia
• , , Germany
• , , Czechia
• , , Lithuania
• , , Finland
• , , Hungary
• , , Poland
• , , Belgium
• , , Italy
• , , Netherlands

View on source registry